Dova Pharmaceuticals (NASDAQ:DOVA) Upgraded at BidaskClub

BidaskClub upgraded shares of Dova Pharmaceuticals (NASDAQ:DOVA) from a buy rating to a strong-buy rating in a report published on Thursday morning, BidAskClub reports.

DOVA has been the topic of several other research reports. Wedbush initiated coverage on shares of Dova Pharmaceuticals in a report on Wednesday, May 22nd. They issued an outperform rating and a $19.00 target price on the stock. Zacks Investment Research downgraded shares of Dova Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, July 16th. JPMorgan Chase & Co. boosted their target price on shares of Dova Pharmaceuticals from $13.00 to $15.00 and gave the stock an underweight rating in a report on Friday, July 12th. Evercore ISI raised shares of Dova Pharmaceuticals from an in-line rating to an outperform rating and set a $15.00 target price on the stock in a report on Monday, July 1st. Finally, HC Wainwright boosted their target price on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a buy rating in a report on Thursday, June 27th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $27.13.

Shares of DOVA traded up $0.37 during mid-day trading on Thursday, reaching $16.14. The stock had a trading volume of 306,371 shares, compared to its average volume of 297,812. Dova Pharmaceuticals has a 12 month low of $5.62 and a 12 month high of $26.49. The business’s fifty day moving average price is $14.20. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.27 and a current ratio of 4.46. The firm has a market capitalization of $445.23 million, a price-to-earnings ratio of -6.21 and a beta of 2.57.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its earnings results on Tuesday, May 7th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.10. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%. The firm had revenue of $4.00 million for the quarter, compared to the consensus estimate of $3.46 million. As a group, equities analysts anticipate that Dova Pharmaceuticals will post -2.21 earnings per share for the current fiscal year.

In related news, insider Jason Hoitt sold 7,580 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $15.26, for a total transaction of $115,670.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive purchased 427,209 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The shares were acquired at an average cost of $13.35 per share, for a total transaction of $5,703,240.15. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 582,854 shares of company stock worth $8,243,825 and have sold 27,807 shares worth $422,464. 60.30% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC raised its stake in shares of Dova Pharmaceuticals by 0.8% in the first quarter. FMR LLC now owns 1,347,521 shares of the company’s stock valued at $11,979,000 after acquiring an additional 10,970 shares during the period. Sanders Morris Harris LLC raised its stake in shares of Dova Pharmaceuticals by 85.1% in the second quarter. Sanders Morris Harris LLC now owns 521,887 shares of the company’s stock valued at $7,359,000 after acquiring an additional 239,972 shares during the period. Geode Capital Management LLC raised its stake in shares of Dova Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock valued at $1,184,000 after acquiring an additional 11,732 shares during the period. Spark Investment Management LLC raised its stake in shares of Dova Pharmaceuticals by 31.8% in the first quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock valued at $715,000 after acquiring an additional 19,400 shares during the period. Finally, Birchview Capital LP raised its stake in shares of Dova Pharmaceuticals by 25.0% in the first quarter. Birchview Capital LP now owns 50,000 shares of the company’s stock valued at $445,000 after acquiring an additional 10,000 shares during the period. 31.03% of the stock is currently owned by institutional investors and hedge funds.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Featured Story: What does it mean to hold a stock in street name?

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.